Avid Bioservices Inc (CDMO)

[biopharm]

Who is behind the operations in China?

We must assume Dr Rolf Brekken trip to China had something to do with all this.....because again, I mentioned and posted that site / translation and it disappeared within hours ... (Thankfully translated and posted the entire article )
____

Rolf Brekken just went to China and some PS Targeting related research with top researchers ....now the link disappears??

Would this be material information that Peregrine Pharmaceuticals is not releasing to all shareholders ??

I translated the Chinese website and attached below is the English text and have the picture of Dr Rolf Brekken saved to prove it....though all here seen it when I initially posted it.

On September 28, Prof. Rolf A Brekken, Director of Surgery Laboratory, Southwestern Medical Center, University of Texas, visited our hospital at the invitation of Professor He Yulong, Director of Gastrointestinal Surgery Center of our hospital. Rolf A Brekken visited our hospital gastrointestinal surgery center and communicated with the gastrointestinal surgery center experts around the tumor immunotherapy to discuss and discuss. Professor Rolf A Brekken gave a lecture entitled "Targeting pathways that drive immune suppression and epithelial plasticity in cancer".

Professor Zhang Changhua of our institute made the "tumor-related macrophages promote the invasion and metastasis of gastric cancer through CXCR2 / STAT3 loop" Reported, Dr. Yu Jie also conducted a research report in Dr. research.

The visit of Professor Rolf A Brekken further enhanced the exchange and cooperation between the two sides, laying a solid foundation for further research on scientific research and personnel training. University of Texas Southwestern Medical Center is the United States of America's top medical education and biomedical scientific research research university, our hospital since 2010 with the United States of America University of Southwest Medical Center established a comprehensive strategic cooperative relations, more than scholars have to go to Southwest Medical Center Learn. (Lin Qiaojie, Cai Murong)

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135374686

In the meantime....Laura E. Benjamin has been working with Peregrine KOL Dr Harold Dvorak
https://www.researchgate.net/publication/301775230_Stromal-Based_Signatures_for_the_Classification_of_Gastric_Cancer

.....and one of the professors in the Dr Brekken trip to China, Dr He Yulong concentrates re: Hematology and on his research gate profile he follows Peregrine KOL Dr Dvorak so why was Dr Laura E. Benjamin chosen ....hmmmm

http://www.bidmc.org/News/PRLandingPage/2014/March/Dvorak.aspx

I doubt Dr Rolf Brekken went to China and subject of his speech was ""Targeting pathways that drive immune suppression and epithelial plasticity in cancer". ....and you think PS Targeting was mentioned? I say YES

_____


Dr He Yulong
Soochow University (PRC)
Location
Suzhou, China
Department
CYRUS TANG HEMOTOLOGY CENTER
Position
Principal Investigator
....

https://www.researchgate.net/profile/Yulong_He3

__________


Yuhui Huang Ph.D.



199 Ren'ai Rd. Suzhou, Jiangsu 215123, P.R.China

Cyrus Tang Hematology Center, Soochow University

Phone: [phone]-3507

Fax: [phone]

Email: [e-mail]

Research:

Despite the major advances in diagnosis and multimodal therapy, cancer remains the leading cause of death in the world. The recent breakthrough in cancer immunotherapies, such as ipilimumab (an anti-CTLA4 antibody), have demonstrated an impressive survival benefit in the treatment of advanced cancer patients and brought active immunotherapy into the limelight. However, cancer immunotherapy still faces many challenges. A critical one is the abnormal tumor microenvironment, which not only impede the delivery of anti-cancer agents, but also limit their effectiveness and induce drug resistance. My laboratory is dedicated to dissecting the molecular and cellular mechanisms in establishing an immunosuppressive tumor microenvironment and to exploring innovative strategies to recondition this environment. The ultimate goal is to translate gained knowledge to develop more selective and effective anti-cancer immunotherapies for cancer patients by integrating tumor immunology, vascular biology, biomarkers, nanotechnology and intravital imaging.

http://ctmi.suda.edu.cn/en/ShowSingleFaculty.aspx?id=136

....another in the group and if you look at his research, Peregrine / CDMO KOL Dr David P. Carbone has worked with him alot ...